Ligand Pharmaceuticals, Inc. (LGND) Misses Q3 EPS by 5c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $262.17 -4.62%
EPS Growth %: +25.6%
Financial Fact:
General and administrative: 6.31M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +25.6%
Financial Fact:
General and administrative: 6.31M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q3 EPS of ($0.01), $0.05 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $6.4 million versus the consensus estimate of $8.4 million.
Separately, the company announced it is restating LFY11, Q112, Q212 financials.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Separately, the company announced it is restating LFY11, Q112, Q212 financials.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
- FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
